Self Antigen Specific CD4 Positive T cells
Self Antigen Specific CD4 Positive T cells
批准号:
8651025
负责人:
James J Moon
金额:
$41.06万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-12-01 至 2018-11-30
关键词:
AchievementAdoptedAntigensAutoantigensAutoimmune DiseasesAutoimmunityBone MarrowCD4 Positive T LymphocytesCellsChimera organismChronicClonal DeletionComplexDevelopmentDiseaseEconomic BurdenEquilibriumFrequenciesGene Expression ProfileGenesGenomeGoalsImmuneImmune ToleranceImmune systemLeftModelingPatternPeptide/MHC ComplexPeptidesPeripheralPhenotypePhysiologicalPlayPopulationRegulatory T-LymphocyteRoleShapesSocietiesSpecificitySymptomsSystemT cell regulationT-LymphocyteTechniquesTechnologyTestingTherapeuticThymus GlandTissuesTransgenic MiceTransgenic OrganismsTumor Immunityautoreactive T cellbasecentral toleranceflexibilityimprovedin vivoinsightnovel strategiespreventpublic health relevancesocialtherapy developmentthymocytetool
中文摘要
项目总结
在中枢耐受的经典范例中,对自身抗原具有特异性的胸腺细胞在
发育,从而使外周T细胞谱系中没有任何能够对自身...
纸巾。虽然这种机制在预防自身免疫方面的重要性已经得到了很好的证实,但仍在增长
有证据表明,许多自身抗原特异的T细胞例行公事地逃避缺失并聚集在外周
不会导致疾病的T细胞谱系。这在组织限制性自身抗原的情况下尤其可能发生。
在胸腺中表达很差的基因。外周血中自身抗原特异性T细胞如何保持耐受
它们的同源抗原的存在提出了一个有趣的问题,因为这些细胞可能参与了
自身免疫和抗肿瘤免疫。由于单抗TCR转基因T细胞的严重局限性
精确模拟抗原特异性T细胞的复杂多克隆群体的细胞系统,几个
关于自身抗原特异性T细胞的基本问题仍然没有解决。首先,目前还不清楚在多大程度上
中枢耐受机制,如克隆性缺失和调节性T细胞(Treg)发育在
调节T细胞对组织限制性自身抗原的反应性。此外,目前还不清楚自身抗原是否
存在于外周的特定常规T细胞(Tconv)在功能上完全忽略了它们的抗原
无能,或被Treg细胞主动抑制。我们开发了强大的实验系统,包括
肽:基于MHC四聚体的细胞浓缩技术和组织限制性抗原转基因小鼠
使我们能够直接表征罕见的自身抗原特异性T细胞的多克隆群体,这种T细胞自然出现在
内生曲目。这些工具将使我们能够以前所未有的水平调查这些问题
生理意义。我们假设自身抗原特异性T细胞的缺失耐受性要小得多
比以前认识到的更广泛,特别是在组织限制性自身抗原的情况下,以及
因此,T细胞的外周谱系通常被许多潜在的自我反应所填充
克隆人。我们认为,自身抗原特异性的CD4+T细胞优先采用Treg血统命运
发育,这些细胞抑制它们在外围的Tconv对应物,以建立耐受性
总的自身抗原特异群。我们将通过追求以下最初的具体情况来检验这一假设
目的:1)确定胸腺选择如何塑造组织特异性的外周CD4+T细胞-
限制性自身抗原,以及2)决定如何在外周人群中维持稳定的耐受性
自身抗原特异性的CD4+T细胞。这些目标的实现将极大地提高我们对
外周T细胞耐受的非缺失机制通常是如何为自身抗原建立的
稳定状态,以及我们如何将这些信息用于治疗目的。
英文摘要
PROJECT SUMMARY
In the classic paradigm of central tolerance, thymocytes with specificity for self-antigens are deleted during
development, thereby leaving the peripheral T cell repertoire devoid of any cells capable of reacting to self-
tissues. While the significance of this mechanism in preventing autoimmunity is well established, growing
evidence indicates that many self-antigen specific T cells routinely escape deletion and populate the peripheral
T cell repertoire without causing disease. This is especially likely in the case of tissue-restricted self-antigens
that are poorly expressed in the thymus. How peripheral self-antigen specific T cells remain tolerant in the
presence of their cognate antigen poses an intriguing question as these cells are likely involved in
autoimmunity as well as anti-tumor immunity. Due to the severe limitations of monoclonal TCR transgenic T
cell systems to accurately model complex polyclonal populations of antigen-specific T cells, several
fundamental questions about self-antigen specific T cells remain unresolved. First, it is unclear to what extent
central tolerance mechanisms such as clonal deletion and regulatory T cell (Treg) development play in the
regulation of T cell reactivity to tissue-restricted self-antigens. Furthermore, it is unclear whether self-antigen
specific conventional T cells (Tconv) present in the periphery are simply ignorant of their antigen, functionally
anergic, or actively suppressed by Treg cells. We have developed powerful experimental systems involving
peptide:MHC tetramer-based cell enrichment techniques and tissue-restricted antigen transgenic mice that
allow us to directly characterize rare polyclonal populations of self-antigen specific T cells that naturally arise in
endogenous repertoires. These tools will enable us to investigate these issues at an unprecedented level of
physiological significance. We hypothesize that deletional tolerance of self-antigen specific T cells is far less
extensive than previously appreciated, particularly in the case of tissue-restricted self-antigens, and
accordingly, the peripheral repertoire of T cells is normally populated with numerous potentially self-reactive
clones. We believe that self-antigen specific CD4+ T cells preferentially adopt a Treg lineage fate during
development, and these cells suppress their Tconv counterparts in the periphery to establish tolerance within
the overall self-antigen specific population. We will test this hypothesis by pursuing the following initial specific
aims: 1) Determine how thymic selection shapes the peripheral repertoire of CD4+ T cells specific for tissue-
restricted self-antigens, and 2) Determine how steady state tolerance is maintained in peripheral populations of
self-antigen specific CD4+ T cells. The achievement of these aims will greatly improve our understanding of
how non-deletional mechanisms of peripheral T cell tolerance are normally established for self-antigens in the
steady state, and how we may exploit this information for therapeutic purposes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomaterials for modulating the gut microbiome for immune activation
-
批准号:10614059
-
项目类别:
-
资助金额:$48.35万
-
财政年份:2022
-
负责人:James J Moon
-
依托单位:
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10608196
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10299254
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
T cell Tolerance to Enteric Commensal Bacteria
-
批准号:10424555
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9292510
-
项目类别:
-
资助金额:$29.34万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9752434
-
项目类别:
-
资助金额:$65.33万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Engineering Nanomaterials to Prime Immunity
-
批准号:10063848
-
项目类别:
-
资助金额:$41.02万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9539522
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Elicitation of mucosal immune responses against HIV
-
批准号:9271737
-
项目类别:
-
资助金额:$9.41万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
-
批准号:9348653
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiforme
-
批准号:9512575
-
项目类别:
-
资助金额:$42.37万
-
财政年份:2016
-
负责人:James J Moon
-
依托单位:
Delivery of Particle Vaccines to Control Trafficking Patterns of T Cells
-
批准号:8226138
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Delivery of Particle Vaccines to Control Trafficking Patterns of T Cells
-
批准号:8600957
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Self Antigen Specific CD4 Positive T cells
-
批准号:9177742
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Self Antigen Specific CD4 Positive T cells
-
批准号:8774179
-
项目类别:
-
资助金额:$41.06万
-
财政年份:2013
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8196496
-
项目类别:
-
资助金额:$15.07万
-
财政年份:2011
-
负责人:James J Moon
-
依托单位:
Role of Cytokines in Naive CD4+ T cell Activation
-
批准号:7055595
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2006
-
负责人:James J Moon
-
依托单位:
Role of Cytokines in Naive CD4+ T cell Activation
-
批准号:7187409
-
项目类别:
-
资助金额:$1.73万
-
财政年份:2006
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8381647
-
项目类别:
-
资助金额:$9.14万
-
财政年份:--
-
负责人:James J Moon
-
依托单位:
Tetramer Core
-
批准号:8707954
-
项目类别:
-
资助金额:$9.39万
-
财政年份:--
-
负责人:James J Moon
-
依托单位:
海外基金